Literature DB >> 6559201

Characterization of the initial C3 convertase of the alternative pathway of human complement.

Z Fishelson, M K Pangburn, H J Müller-Eberhard.   

Abstract

C3(H2O),Bb, the initial C3 convertase of the alternative complement pathway, was demonstrated to be a metal-containing protein complex by sucrose density gradient ultracentrifugation. Demonstration of this labile enzyme became possible by increasing its half-life with nickel instead of magnesium ions used for enzyme formation. The enzyme was generated from C3, the internal thioester bond of which was hydrolyzed (C3(H2O)), and from 125I-Factor B and Factor D. The sedimentation coefficient of the enzyme complex was 10.7S. By using 63Ni for enzyme formation, the metal ion was detected in the enzyme complex after ultracentrifugation in the presence of 10 mM EDTA. The stoichiometry of the constituents in the C3(H2O),Bb(Ni) complex was 1:1:1. To verify that C3 is incorporated into the enzyme complex in the form of C3(H2O), the enzyme complex was adsorbed to anti-Factor B-Sepharose and subjected to decay-dissociation. Examination of the subsequently eluted protein by SDS gel electrophoresis under reducing conditions demonstrated the presence of an intact C3 alpha-chain. This work provides further evidence that a C3 convertase can be generated from noncleaved C3 that is modified at the thioester site. With the use of a fluorometric assay, the activity (kcat/Km) and the half-life of the initial C3 convertase were determined and compared to those of C3b,Bb.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6559201

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  Use of time-resolved FRET to validate crystal structure of complement regulatory complex between C3b and factor H (N terminus).

Authors:  Isabell C Pechtl; Robert K Neely; David T F Dryden; Anita C Jones; Paul N Barlow
Journal:  Protein Sci       Date:  2011-12       Impact factor: 6.725

2.  The pathogenesis of hyaline arteriolosclerosis.

Authors:  C N Gamble
Journal:  Am J Pathol       Date:  1986-03       Impact factor: 4.307

3.  Insights into complement convertase formation based on the structure of the factor B-cobra venom factor complex.

Authors:  Bert J C Janssen; Lucio Gomes; Roman I Koning; Dmitri I Svergun; Abraham J Koster; David C Fritzinger; Carl-Wilhelm Vogel; Piet Gros
Journal:  EMBO J       Date:  2009-07-02       Impact factor: 11.598

Review 4.  The alternative pathway of complement.

Authors:  M K Pangburn; H J Müller-Eberhard
Journal:  Springer Semin Immunopathol       Date:  1984

5.  The C3 convertase of the alternative pathway of human complement. Enzymic properties of the bimolecular proteinase.

Authors:  M K Pangburn; H J Müller-Eberhard
Journal:  Biochem J       Date:  1986-05-01       Impact factor: 3.857

6.  The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb).

Authors:  Fredrik Bexborn; Per Ola Andersson; Hui Chen; Bo Nilsson; Kristina N Ekdahl
Journal:  Mol Immunol       Date:  2007-12-21       Impact factor: 4.407

7.  Leishmanial protein kinases phosphorylate components of the complement system.

Authors:  T Hermoso; Z Fishelson; S I Becker; K Hirschberg; C L Jaffe
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598

Review 8.  Initiation and regulation of complement during hemolytic transfusion reactions.

Authors:  Sean R Stowell; Anne M Winkler; Cheryl L Maier; C Maridith Arthur; Nicole H Smith; Kathryn R Girard-Pierce; Richard D Cummings; James C Zimring; Jeanne E Hendrickson
Journal:  Clin Dev Immunol       Date:  2012-10-16

9.  A novel inhibitor of the alternative pathway of complement reverses inflammation and bone destruction in experimental arthritis.

Authors:  Kenneth J Katschke; Karim Y Helmy; Micah Steffek; Hongkang Xi; Jianping Yin; Wyne P Lee; Peter Gribling; Kai H Barck; Richard A D Carano; Robin E Taylor; Linda Rangell; Lauri Diehl; Philip E Hass; Christian Wiesmann; Menno van Lookeren Campagne
Journal:  J Exp Med       Date:  2007-06-04       Impact factor: 14.307

10.  Evidence for a gamma-interferon receptor that regulates macrophage tumoricidal activity.

Authors:  A Celada; P W Gray; E Rinderknecht; R D Schreiber
Journal:  J Exp Med       Date:  1984-07-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.